about
Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project.Separation and structural characterization of the new synthetic cannabinoid JWH-018 cyclohexyl methyl derivative "NE-CHMIMO" using flash chromatography, GC-MS, IR and NMR spectroscopy.Genotoxic properties of XLR-11, a widely consumed synthetic cannabinoid, and of the benzoyl indole RCS-4.Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples.Immunoassay screening in urine for synthetic cannabinoids - an evaluation of the diagnostic efficiency.Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples.Reply to 'Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA'.In vitro metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stability.Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA.Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE.Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus.Detection and quantification of 56 new psychoactive substances in whole blood and urine by LC-MS/MS.Investigations of the genotoxic properties of two synthetic cathinones (3-MMC, 4-MEC) which are used as psychoactive drugsMetabolites of synthetic cannabinoids in hair--proof of consumption or false friends for interpretation?[Desoxypipradrol - a new (already well known) designer drug]Characterization and in vitro phase I microsomal metabolism of designer benzodiazepines: An update comprising flunitrazolam, norflurazepam, and 4'-chlorodiazepam (Ro5-4864)Method validation and preliminary pharmacokinetic studies on the new designer stimulant 3-fluorophenmetrazine (3-FPM)Cumyl-PEGACLONE: A comparatively safe new synthetic cannabinoid receptor agonist entering the NPS market?
P50
Q33166685-FD9AF8BC-63A8-4E34-85E3-B929118CCBF9Q34530742-C8F1EE57-F1B8-4C9A-AC46-C688CF90800DQ37408099-A21F2D19-CE4D-4D42-9B18-FF7E64C0C442Q38858777-1A3B4361-D610-4036-911B-BFE766528C0CQ38994109-19DF0DDF-B93C-4543-8A08-25DCD444E67BQ39508464-6A9DE79A-5C39-4F54-A06B-3F31E3D7825AQ42751396-685B252A-4B35-4C68-A63D-BD5C65F097D8Q46594306-7587D488-2708-42A9-BC18-0954A0FAB9E2Q47598189-9A289C06-CDFA-4AED-8EE9-01DEA8210AA1Q48058551-8A790DAB-138F-4258-8D31-EC2746219039Q50674127-9C665280-DDAC-46A8-9407-282C656D0AEAQ53479625-77B85E04-F537-48D4-858B-37278FD0A722Q64389902-E7D85DDA-4227-4140-B023-5F7104B11DB4Q87402638-3B98E41A-C1C4-4042-AAF7-CA26F34D6ABDQ87786383-A987A35A-C7D7-4686-886C-B29286B1383CQ90713993-9383E8A6-0C16-46DC-8D9D-C20CB4E94BF0Q91735640-98AA2943-F995-4035-B60B-294A5D5F1C4BQ93368379-BEE72AEB-C7A2-4EEC-ABFB-92620277FE43
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Verena Angerer
@en
Verena Angerer
@nl
type
label
Verena Angerer
@en
Verena Angerer
@nl
prefLabel
Verena Angerer
@en
Verena Angerer
@nl
P31
P496
0000-0002-3081-4609